Effect of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice

摘要: Cyclophosphamide (CP) is one of the commonly used anticancer drugs, but its use limited by myelotoxicity. Nerolidol (NER) a lipophilic, bioactive sesquiterpene reported to have neuroprotective, cardioprotective, gastroprotective, and renal protective potential, myeloprotective potential underexplored. This study was aimed at evaluating myeloid-protective NER in CP-induced myelotoxic mice. 200 400 mg/kg given orally from first 14th day. CP administered intravenously on seventh At end study, mice were humanly killed, blood bone marrow collected stored for hematologic, biochemical histopathologic estimations. Bone analysis revealed reduced cellularity, α-esterase activity, colony-forming unit granulocyte–macrophage (CFU-GM) levels, erythroid (CFU-E) burst-forming unit-erythroid (BFU-E) levels. Hematologic findings peripheral count granulocyte-colony stimulating factor (G-CSF) whereas increased malondialdehyde (MDA), tumor necrosis α (TNF-α), interleukin (IL)-6, IL-1β levels superoxide dismutase (SOD), catalase (CAT), IL-10 Histopathologic further strengthened our findings. Treatment with significantly reversed hematotoxic aberrations retained structural integrity marrow. Findings current suggest that therapeutic molecule can mitigate manifestations. However, more detailed studies are needed explicate mechanism underlying effect.